100+ Free Cert Gastroenterology(SA) Phys Practice Questions

Prepare for the CMSA Sub-specialty Certificate in Gastroenterology Cert Gastroenterology(SA) Phys — South Africa exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More CMSA Sub-specialty Certificate Examinations (South Africa)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

CMSA Sub-specialty Certificate in Allergology Cert Allerg(SA) Phys — South Africa

Practice Questions100 questions

CMSA Sub-specialty Certificate in Cardiology Cert Cardiology(SA) Paed — South Africa

Practice Questions100 questions

CMSA Sub-specialty Certificate in Cardiology Cert Cardiology(SA) Phys — South Africa

Practice Questions100 questions

CMSA Sub-specialty Certificate in Clinical Haematology Cert Clin Haematology(SA) Paed — South Africa

Practice Questions100 questions

CMSA Sub-specialty Certificate in Clinical Haematology Cert Clin Haematology(SA) Path — South Africa

Practice Questions100 questions

CMSA Sub-specialty Certificate in Clinical Haematology Cert Clin Haematology(SA) Phys — South Africa

Practice Questions100 questions

2026 Statistics

Key Facts: Cert Gastroenterology(SA) Phys Exam

2 components

Written + oral/OSCE

CMSA Regulations

50% each

Subminimum per component

CMSA Regulations

R24 650

Exam Fee

CMSA Fee Schedule

Sub-specialty

Exam Level

College of Physicians SA

CMSA

Exam Body

Colleges of Medicine of South Africa

The Cert Gastroenterology(SA) Phys is a rigorous two-component sub-specialty exit examination (written short-answer papers plus an oral/OSCE/clinical component, each 50%) evaluating expert clinical competence in gastroenterology, hepatology, and interventional endoscopy for specialist physicians in South Africa. This bank provides 100 practice MCQs as a study aid.

Sample Cert Gastroenterology(SA) Phys Practice Questions

Try these sample questions to test your Cert Gastroenterology(SA) Phys exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 28-year-old female presents with a 6-week history of 5 to 6 bloody bowel movements daily, left lower quadrant abdominal cramping, and tenesmus. Sigmoidoscopy reveals continuous mucosal erythema, loss of vascular pattern, and granularity extending from the rectum up to 35 cm. Biopsies confirm chronic ulcerative colitis. Which of the following is the most appropriate first-line induction and maintenance regimen?

A.Topical mesalazine 1 g suppository daily combined with oral mesalazine 2.4 g to 4.8 g daily

B.Oral mesalazine 1.2 g daily alone

C.Oral prednisone 40 mg daily as monotherapy

D.Intravenous infliximab 5 mg/kg at weeks 0, 2, and 6

Explanation: For mild-to-moderate left-sided ulcerative colitis, high-level evidence and international guidelines (ECCO, ACG, SAGES) recommend combination therapy with oral 5-ASA (mesalazine 2.4 g – 4.8 g daily) plus topical 5-ASA (mesalazine 1 g suppository or enema daily). Combination therapy is significantly superior to either oral or topical mesalazine monotherapy for rapid symptom resolution and mucosal healing.

2A 32-year-old male with chronic diarrhea and weight loss undergoes colonoscopy. Endoscopy shows multiple deep linear ulcers separated by normal mucosal mucosa ('cobblestoning') in the terminal ileum and ascending colon, with sparing of the rectum. Histopathological examination of biopsies reveals non-caseating granulomas within the submucosa. Which feature is most pathognomonic for Crohn's disease over Ulcerative Colitis?

A.Transmural inflammation and non-caseating epithelial granulomas

B.Crypt abscesses and architectural distortion

C.Continuous mucosal involvement starting from the anal verge

D.Depletion of goblet cell mucin in mucosal crypts

Explanation: Non-caseating epithelial granulomas and transmural inflammation spanning across all gut wall layers are hallmark features of Crohn's disease. Ulcerative colitis is characterized by mucosal and submucosal inflammation limited to the colon, whereas Crohn's can affect any part of the GI tract from mouth to anus with discontinuous ('skip') lesions.

3A 35-year-old male is admitted to the medical ward with acute severe ulcerative colitis (ASUC) fulfilling Truelove and Witts criteria (8 bloody stools/day, temperature 38.2°C, heart rate 104 bpm, CRP 68 mg/L). He is initiated on IV hydrocortisone 100 mg 6-hourly. On day 3 of intravenous corticosteroid therapy, he continues to pass 7 bloody stools per day and his CRP is 45 mg/L. According to the Oxford (Travis) criteria, what is his risk of requiring emergency colectomy during this admission?

A.85% to 90%

B.100%

C.Approximately 15%

D.Approximately 35%

Explanation: According to the Oxford (Travis) criteria, patients with ASUC evaluated on Day 3 of IV corticosteroid therapy who have >8 bloody stools per day OR 3 to 8 bloody stools per day accompanied by a CRP >45 mg/L have an 85% risk of requiring colectomy during that admission. This mandates immediate discussion of rescue therapy (infliximab or ciclosporin) or surgery.

4A 29-year-old female with steroid-refractory acute severe ulcerative colitis on Day 3 of high-dose IV hydrocortisone is evaluated for medical rescue therapy. Stool PCR for Clostridioides difficile and rectal biopsies for CMV IHC are negative. Which statement correctly describes the comparative efficacy of intravenous Infliximab versus intravenous Ciclosporin in this setting?

A.Infliximab and Ciclosporin show equivalent short-term and long-term colectomy-free survival rates

B.Ciclosporin is significantly superior to Infliximab in reducing 90-day colectomy rates

C.Infliximab is significantly superior to Ciclosporin in achieving clinical remission at 7 days

D.Sequential therapy with Infliximab immediately following failed Ciclosporin is standard safe practice

Explanation: Head-to-head randomized trials (GETAID CYCLICAL trial and UK CONSTRUCT trial) demonstrated equivalent efficacy between IV Infliximab (5 mg/kg) and IV Ciclosporin (2 mg/kg) for steroid-refractory ASUC in terms of short-term response, 90-day colectomy rates, and long-term colectomy-free survival. Infliximab is often preferred due to ease of administration and lack of need for therapeutic drug level monitoring.

5A 26-year-old male with Crohn's disease presents with complex perianal disease consisting of two trans-sphincteric fistulae discharging purulent material. Pelvic MRI confirms active fistulous tracts with a 1.5 cm fluid collection in the ischioanal fossa. What is the most appropriate initial management strategy?

A.Immediate high-dose anti-TNF monotherapy with Infliximab

B.Fistulotomy cutting through the sphincter complex

C.Long-term systemic corticosteroids combined with oral metronidazole

D.Surgical incision and drainage of the abscess with non-cutting seton placement, combined with antibiotics and anti-TNF therapy

Explanation: The optimal multidisciplinary approach for complex fistulizing perianal Crohn's disease involves: (1) prompt surgical control of sepsis via incision/drainage of perianal abscesses and non-cutting seton insertion, (2) temporary antibiotic therapy (ciprofloxacin/metronidazole), and (3) induction and maintenance anti-TNF therapy (Infliximab), ideally combined with a thiopurine (combination therapy).

6Prior to initiating Azathioprine in a 30-year-old female with steroid-dependent Crohn's disease, baseline Thiopurine S-methyltransferase (TPMT) enzymatic testing is performed. The report shows low TPMT enzyme activity (intermediate metabolizer). What dosage adjustment is recommended?

A.Increase Azathioprine dose to 3.5 mg/kg/day

B.Administer full standard dose of Azathioprine (2.0 to 2.5 mg/kg/day)

C.Azathioprine is strictly contraindicated in intermediate TPMT metabolizers

D.Reduce Azathioprine target dose by 30% to 50% of the standard dose

Explanation: TPMT testing identifies patients at risk for severe azathioprine-induced myelosuppression. Intermediate metabolizers (heterozygous low/intermediate TPMT activity) accumulate high levels of active cytotoxic 6-thioguanine nucleotides (6-TGN) if given standard doses; guidelines recommend starting at 30%–50% of the standard dose (e.g. 1.0–1.25 mg/kg/day) with frequent CBC monitoring. Absent TPMT activity requires complete avoidance or >90% dose reduction.

7A 34-year-old male with Crohn's disease on Azathioprine 150 mg daily presents with persistent mucosal inflammation. Thiopurine metabolite monitoring reveals a subtherapeutic 6-TGN level of 115 pmol/8x10^8 RBCs (target 235-450) and an elevated 6-MMP level of 11,200 pmol/8x10^8 RBCs (threshold >5700 associated with hepatotoxicity). Serum ALT is elevated at 142 U/L. What is the most effective pharmacological strategy to optimize thiopurine therapy in this 'thioperoxidase preferential shunter'?

A.Switch Azathioprine to Mercaptopurine at equivalent dose

B.Add low-dose Allopurinol (100 mg daily) and reduce Azathioprine dose to 25%-33% of original dose

C.Discontinue Azathioprine and initiate high-dose methotrexate IV

D.Increase Azathioprine dose to 250 mg daily

Explanation: Thiopurine shunting (hypermethylation) is characterized by low 6-TGN and excessively high 6-MMP levels, causing therapeutic failure and hepatotoxicity. Adding low-dose Allopurinol (100 mg daily) inhibits xanthine oxidase, shifting metabolism toward 6-TGN production. Because Allopurinol dramatically increases 6-TGN levels, the azathioprine dose MUST be reduced to 25%–33% of the original dose (e.g., 37.5–50 mg/day) with mandatory blood count monitoring.

8According to international surveillance guidelines (ECCO/BSG/ACG), when should routine surveillance colonoscopy for colorectal cancer (CRC) screening begin in a patient with extensive ulcerative colitis (pancolitis)?

A.8 years after symptom onset

B.At age 50 years, following general population screening guidelines

C.15 years after symptom onset

D.Immediately upon initial clinical diagnosis regardless of duration

Explanation: Colorectal cancer surveillance colonoscopy in patients with extensive ulcerative colitis or Crohn's colitis (involving >1/3 of colon) should commence 8 years after the onset of IBD symptoms (not date of diagnosis). In patients with concomitant Primary Sclerosing Cholangitis (PSC), surveillance begins immediately upon PSC diagnosis and continues annually.

9A 42-year-old male with ulcerative colitis is diagnosed with Primary Sclerosing Cholangitis (PSC) after MRCP demonstrates focal strictures and dilations of intrahepatic and extrahepatic bile ducts. Which recommendation regarding colorectal cancer surveillance is mandatory for this patient?

A.Surveillance colonoscopy is not required if liver biochemistry normalizes

B.Annual surveillance colonoscopy with chromoendoscopy starting immediately upon diagnosis of PSC

C.Surveillance colonoscopy every 3 years starting 8 years after UC diagnosis

D.Colonoscopy every 5 years starting at age 50

Explanation: The presence of Primary Sclerosing Cholangitis (PSC) in patients with IBD dramatically increases the risk of colorectal dysplasia and adenocarcinoma (up to 4-fold to 5-fold higher than IBD alone). Guidelines recommend annual surveillance colonoscopy with high-definition chromoendoscopy and targeted biopsies starting immediately upon PSC diagnosis, regardless of IBD activity or duration.

10A 31-year-old female with ileocolonic Crohn's disease achieved clinical remission on Infliximab 5 mg/kg every 8 weeks. After 14 months of stable therapy, she presents with secondary loss of response (recurrent abdominal pain, diarrhea, CRP 38 mg/L). Reactive therapeutic drug monitoring (TDM) reveals a trough Infliximab level of <0.5 µg/mL and high-titer anti-infliximab antibodies (ADA >200 ng/mL). What is the most appropriate management step?

A.Increase Infliximab dose to 10 mg/kg every 4 weeks

B.Switch to a second anti-TNF agent (Adalimumab) or a non-anti-TNF biologic (e.g. Ustekinumab or Vedolizumab)

C.Add Azathioprine monotherapy and discontinue Infliximab

D.Add oral prednisone 40 mg daily and continue Infliximab at current dose

Explanation: When secondary loss of response to infliximab is driven by high-titer anti-drug antibodies (immunogenic loss of response) accompanied by undetectable or low drug levels, dose escalation of infliximab is ineffective as the antibodies rapidly clear the drug. The patient should be switched out-of-class (e.g., Ustekinumab, Vedolizumab, or Risankizumab) or to a second anti-TNF (Adalimumab), ideally with immunomodulator co-therapy to prevent anti-drug antibody formation against the new agent.

About the Cert Gastroenterology(SA) Phys Exam

The Sub-specialty Certificate in Gastroenterology of the College of Physicians of South Africa - Cert Gastroenterology(SA) Phys - is the professional sub-specialty exit qualification for gastroenterologists in South Africa. The examination tests advanced clinical, pathophysiological, diagnostic, and therapeutic knowledge in all aspects of luminal gastroenterology, hepatology, pancreatico-biliary disease, and interventional endoscopy.

Assessment

Two components each contributing 50%: a written component (short-answer written papers) and an oral/OSCE/OSPE/clinical component. Content spans 5 domain areas: Inflammatory Bowel Disease (25%), Hepatology (25%), Luminal Gastroenterology (20%), Pancreatico-Biliary Diseases (15%), and Diagnostic & Interventional Endoscopy (15%).

Time Limit

Written short-answer papers plus an OSCE and viva component.

Passing Score

Overall pass mark 50% with a 50% subminimum in each of the two components (written and oral/OSCE/OSPE/clinical).

Exam Fee

R24 650 (Colleges of Medicine of South Africa (CMSA), College of Physicians)

Cert Gastroenterology(SA) Phys Exam Content Outline

25%

Inflammatory Bowel Disease (Crohn's, Ulcerative Colitis)

Diagnosis, disease activity stratification, medical therapeutics (5-ASAs, corticosteroids, immunomodulators, biologics, small molecules), acute severe ulcerative colitis, perianal Crohn's, dysplasia surveillance, pouchitis, and SIBO.

25%

Hepatology (Viral Hepatitis, Cirrhosis, Liver Transplantation)

Acute and chronic viral hepatitis (HBV, HCV, HDV, HEV), autoimmune liver disease (AIH, PBC, PSC), metabolic liver diseases (MASH, Wilson's, Hemochromatosis), cirrhosis complications (variceal bleeding, SBP, HRS, HE), acute liver failure, HCC surveillance, and liver transplantation.

20%

Luminal Gastroenterology, Barrett's, Coeliac Disease

Esophageal disorders (GERD, Barrett's esophagus, EoE, motility disorders/achalasia), gastric and duodenal diseases (H. pylori, peptic ulcer, atrophic gastritis, GIST), coeliac disease and enteropathies, malabsorption, short bowel syndrome, and hereditary polyposis syndromes.

15%

Pancreatico-Biliary Diseases

Acute pancreatitis management and complications, chronic pancreatitis, exocrine pancreatic insufficiency, pancreatic cystic lesions (IPMN, MCN), autoimmune pancreatitis (Type 1 and 2), acute cholangitis, choledocholithiasis, cholangiocarcinoma, and post-ERCP pancreatitis prevention.

15%

Diagnostic & Interventional Endoscopy

Quality indicators in colonoscopy (ADR, cecal intubation), polypectomy (EMR, ESD), acute upper and lower GI bleeding management, endoscopic treatment of perforations, EUS FNA/FNB, enteroscopy, sedation and safety, endoscope reprocessing, and therapeutic biliary/pancreatic stenting.

How to Pass the Cert Gastroenterology(SA) Phys Exam

What You Need to Know

Passing score: Overall pass mark 50% with a 50% subminimum in each of the two components (written and oral/OSCE/OSPE/clinical).
Assessment: Two components each contributing 50%: a written component (short-answer written papers) and an oral/OSCE/OSPE/clinical component. Content spans 5 domain areas: Inflammatory Bowel Disease (25%), Hepatology (25%), Luminal Gastroenterology (20%), Pancreatico-Biliary Diseases (15%), and Diagnostic & Interventional Endoscopy (15%).
Time limit: Written short-answer papers plus an OSCE and viva component.
Exam fee: R24 650

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Cert Gastroenterology(SA) Phys Study Tips from Top Performers

1Master current clinical practice guidelines from SAGES, ECCO, EASL, AASLD, and ACG regarding biologic positioning, acute severe UC protocols, DAA regimens, and cirrhosis management.

2Review high-yield interventional endoscopy techniques including EMR, ESD, EUS-guided procedures, and management of endoscopic complications.

3Understand complex hepatology scenarios including liver transplantation evaluation, acute-on-chronic liver failure (ACLF), and management of refractory portal hypertension.

Frequently Asked Questions

What is the format of the CMSA Cert Gastroenterology(SA) Phys examination?

The exit examination has two components, each contributing 50%: a written component (short-answer written papers) and an oral/OSCE/OSPE/clinical component. Candidates must achieve an overall 50% with a 50% subminimum in each component. This free question bank provides 100 practice MCQs as a study aid and does not replicate the official format.

Who is eligible to sit the Cert Gastroenterology(SA) Phys exam?

Candidates must hold the FCP(SA) or an equivalent qualification in Internal Medicine, be registered with the HPCSA as a specialist physician, and have completed accredited sub-specialty fellowship training in gastroenterology.

What topics are covered in the Cert Gastroenterology(SA) Phys blueprint?

The exam is divided into 5 core domains: Inflammatory Bowel Disease (25%), Hepatology (25%), Luminal Gastroenterology (20%), Pancreatico-Biliary Diseases (15%), and Diagnostic & Interventional Endoscopy (15%).